Capricor Therapeutics Class Action After FDA Data Concerns

Capricor Therapeutics faces a class action filed August 11, 2026, alleging it misled investors about Deramiocel and changes to the HOPE-3 statistical-analysis plan. The lawsuit follows FDA briefing documents released in July that raised concerns and preceded a sharp late-July share decline.

Class Actions and Allegations

Multiple securities class actions filed on August 11 name Capricor Therapeutics and certain senior executives, alleging securities fraud under Sections 10(b) and 20(a) of the Securities Exchange Act. The complaints claim the company misrepresented Deramiocel and the integrity of the HOPE-3 clinical data supporting its biologics license application (BLA).

The litigation ties to FDA briefing documents and a July advisory committee process. The class period runs from December 17, 2025, through July 26, 2026, with a lead-plaintiff deadline of September 28, 2026. One complaint, captioned Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385, was filed in the U.S. District Court for the Southern District of California. Law firms Kaplan Fox and Robbins LLP have urged shareholders to consider lead-plaintiff filings.

The complaints allege Capricor failed to disclose changes to the pre-specified statistical-analysis plan (SAP) for HOPE-3 and that the FDA had not agreed to those changes before the BLA resubmission. The FDA issued a Complete Response Letter in July 2025, stating the application lacked substantial evidence of effectiveness and requested additional clinical data.

FDA Briefing Documents and Market Impact

FDA briefing documents released on July 27, 2026, raised concerns about post-hoc changes to the HOPE-3 SAP, including endpoint definitions, analytical methods, and data-imputation strategies. FDA reviewers described the resulting analyses as post-hoc and exploratory, noting the final SAP was not submitted for FDA review before the BLA submission.

The advisory committee voted 9-3 against finding sufficient evidence of effectiveness for the Duchenne muscular dystrophy (DMD)-related cardiomyopathy indication. Capricor publicly disclosed the advisory committee vote on July 30, and the Prescription Drug User Fee Act (PDUFA) target action date remained August 22, 2026.

The FDA briefing documents coincided with a 64.5% share decline, with Capricor’s stock falling from $19.70 on July 24 to $7.00 on July 27. Earlier securities investigation notices characterized the decline as roughly 60% to 70%, attributing it to concerns raised by the briefing documents and flagged post-randomization SAP changes.

Law-firm notices urging shareholders to seek recovery of losses and setting timetables for lead-plaintiff applications have created an immediate layer of investor-facing litigation risk tied to the FDA briefing-document concerns.